Stifel Nicolaus analyst Benjamin Burnett maintained a Hold rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price ...
Keeping a Buy rating and $155 price target on Blueprint Medicines (BPMC), Stifel says the market is disappointed that 2025 Ayvakit guidance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback